Skip to content

18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis

Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02287792
Acronym
TEPvENDO
Enrollment
150
Registered
2014-11-11
Start date
2015-04-17
Completion date
2017-01-31
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Endocarditis

Keywords

Infective endocarditis, 18-FDG PET/CT, Impact, Patient's management, Diagnostic

Brief summary

The purpose of this study is to assess the impact of 18-FDG positron emission tomography (PET)/computed tomography (CT) imaging in the management of patients with suspected or proven IE in detecting cardiac valve damages and other extracardiac complications. The study will evaluate whether this procedure can change the clinical decisions (treatments, valve surgery, patients' overall care) and modify the diagnosis of IE.

Detailed description

Introduction: Infective endocarditis (IE) is a rare disease, often difficult to diagnose with a high mortality rate. Extra-cardiac manifestations, which can occur in 30 to 80% of cases, impact the outcome of the disease. Identifying these manifestations may help confirm an uncertain diagnosis and optimize patients' management. 18-FDG PET/CT imaging, widely used for cancer staging, may also detect hyper-metabolic areas related to extracardiac infectious complications of IE. It provides the opportunity to detect all extracardiac IE infectious complications through a single examination. The impact of 18-FDG PET/CT imaging on the management of IE has yet to be completely evaluated. Hypothesis: 18-FDG PET/CT implementation could result in both shortening of the initial diagnostic work-up of IE and therapeutic optimization. Primary objective: To evaluate the impact of 18-FDG PET/CT on patients' management, as measured by changes in IE therapeutic plans. Secondary objectives: * To evaluate the impact of 18-FDG PET/CT on the Duke-Li criteria for IE diagnosis * To evaluate the performance of 18-FDG PET/CT in detecting valve damages and extracardiac complications induced by the IE * To evaluate whether 18-FDG PET/CT may help identify the infection's portal of entry * To evaluate whether the detection of extracardiac complications by FDG PET/CT is associated with the 6-months survival rate * To identify clinical and biological determinants of extracardiac IE localizations and prognosis * To determine the inter-reader interpretation of the18-FDG PET/CT results and the reproducibility in preparation and acquisition method

Interventions

PROCEDURE18-FDG PET/CT scan

Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subjects aged ≥ 18 years 2. Presenting IE Duke-Li definite - Duke-Li possible or strong suspicion of IE Duke-Li not definite or possible, with initiation of IE antibiotic therapy. 3. Transthoracic or transesophageal ultrasound performed. 4. A stable clinical condition which does not require immediate surgery or contraindicate patient mobilization 5. Absence of cardiac surgery for the current IE episode 6. Covered by the French health insurance system 7. Having given and signed the written study informed consent to the study.

Exclusion criteria

1. Patient having already had a 18-FDG PET/CT in the current episode 2. Contraindication to perform a 18-FDG PET/CT 3. Early prosthetic valve IE (cardiac surgery within last 2 months) 4. Inability to understand the information form 5. Pregnant or lactating woman. 6. Cardiac surgery between inclusion and 18-FDG PET/CT 7. Participation to any clinical trial including 18-FDG PET/CT

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with a change in IE therapeutic plan7 daysat least one modification in antimicrobial or anticoagulant therapy (types, route, dose, number, duration, indication…) or any modification of surgery (type, timing, indications…)

Secondary

MeasureTime frameDescription
Proportion of patients with Duke-Li classification modifications6 monthsProportion of patients with change in diagnostic classification of IE (definite, possible, excluded) according to the Duke-Li classification
Performances of 18-FDG PET/CT in detection of IE localization as compared to other usual procedures6 months1/ in detecting valve damages and extracardiac complications and 2/ in identify the portal of entry of IE
6-month mortality rate6 monthsnumber of dead patients 6 months after inclusion
Determinants of change in therapeutic plan as defined in primary outcome6 monthsClinical and biological determinants of therapeutic changes
18-FDG PET/CT inter-reader reproducibility6 monthsquestionnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026